IN-TIME

IN-TIME

Influence of Home Monitoring on the Clinical Status of Heart Failure Patients

IN-TIME is the first randomized trial to demonstrate a reduction in mortality in heart failure patients with implant-based remote monitoring.

Study Design

  • Randomized, controlled, international, multicenter study
  • To assess the impact of BIOTRONIK Home Monitoring® on the clinical status of heart failure patients.
  • 664 patients at 36 centers

Key Result 1

At 12 months follow-up, significantly fewer patients in the BIOTRONIK Home Monitoring® group worsened according to the modified Packer score compared to the control group (18.9% vs27.5%; p>

  • > 30% Risk Reduction for Worsening of Clinical Status
圖片
Primary Endpoint of INTIME

Key Result 2

Significant reduction of all-cause mortality in heart failure patients (> 50 %) and beneficial effect on the composite clinical score with implant-based (ICD or CRT-D) BIOTRONIK Home Monitoring® compared to standard care.

圖片
Secondary Endpoint of INTIME

Clinical Relevance

  • The IN-TIME study demonstrated improved clinical status for heart failure patients by implementing a remote monitoring system based on:
  • A reliable transmission rate of 85%
  • A clinically relevant set of rhythmological and technical parameters
  • Clinical workflow that enables fast patient contact and follow-up within one to two working days
  • The European Society of Cardiology added a clear recommendation for the use of implant-based remote follow-up to its guidelines.1

Reference no.
  • NCT00538356
1° Endpoints
  • Modified Packer score: based on death, hospitalization, change in NYHA class, patient’s global self-assessment score
2° Endpoints
  • All–cause mortality
  • Number of HF hospitalizations and length(s) of stay
Clinical Sites
  • 36 centers (Australia, Austria, Czech Republic, Denmark, Germany, Israel and Latvia)
Sample Size
  • 664 patients
Inclusion Criteria
  • ICD indication (dual-chamber ICD, CRT-D)
  • Chronic heart failure
  • NYHA class II or III
  • LVEF ≤ 35%
Main Exclusion Criteria
  • Permanent atrial fibrillation
Devices
  • ICD and CRT-D
Flowchart Study Flowchart
Follow-Up
  • 12 months after randomization
Study Duration
  • From July 2007 to December 2010
Principal Investigators
  • Prof. Dr. Gerhard Hindricks, Herzzentrum Leipzig, Germany

Download Section


Related Products

Cardiac Resynchronization Therapy

BIOTRONIK offers an extensive product portfolio in the area of Cardiac Resynchronization.

Tachycardia Therapy

Cardiac Remote Monitoring

BIOTRONIK offers Home Monitoring for its complete product portfolio.

Monitoring Teaser

1 Brignole M et al. 2013 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy. European Heart Journal. 2013, 34(29)